“…Patients with JME develop typically, and intellectual disability is rare ( Wandschneider et al, 2012 ; Iqbal et al, 2015 ; Abarrategui et al, 2018 ; Sezikli et al, 2018 ; Almane et al, 2019 ; Chawla et al, 2021 ). Some cognitive domains might be altered (e.g., executive function), and depression, anxiety, impulsivity, and social or psychiatric problems are common ( Wandschneider et al, 2012 ; de Araujo Filho and Yacubian, 2013 ; Iqbal et al, 2015 ; Abarrategui et al, 2018 ; Sezikli et al, 2018 ; Almane et al, 2019 ; Syvertsen et al, 2019 ; Gama et al, 2020 ; Taura et al, 2020 ; Chawla et al, 2021 ). JME is responsive to anti-seizure medications in 65–92% of patients, though it often requires lifelong treatment ( Yacubian, 2017 ; see Table 1 ).…”